Fibroblast growth factor 19 reverses locomotor impairment and muscle weakness through musculoskeletal recovery in experimental cerebral palsy

Cerebral Palsy (CP) is among the major categories of neuromotor developmental disabilities, including delay in motor skills related to muscle atrophy. Despite these known musculoskeletal damages, current treatments are unable to reverse these primary damages. Thus, Fibroblast Growth Factor 19 (FGF19) stands out for its therapeutic potential to restore muscle structure in muscle atrophy models, but the literature is scarce regarding its effects in models of neurological diseases such as CP.